Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 2
1995 3
1996 1
1997 2
1998 21
1999 57
2000 86
2001 193
2002 345
2003 416
2004 593
2005 715
2006 770
2007 914
2008 900
2009 918
2010 933
2011 924
2012 1017
2013 1033
2014 1092
2015 1022
2016 1123
2017 1079
2018 1066
2019 1049
2020 878
Text availability
Article attribute
Article type
Publication date

Search Results

15,194 results
Results by year
Filters applied: . Clear all
Page 1
Psoriasis.
Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY, Gottlieb AB. Greb JE, et al. Nat Rev Dis Primers. 2016 Nov 24;2:16082. doi: 10.1038/nrdp.2016.82. Nat Rev Dis Primers. 2016. PMID: 27883001 Review.
Infliximab-Related Infusion Reactions: Systematic Review.
Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Lichtenstein L, et al. J Crohns Colitis. 2015 Sep;9(9):806-15. doi: 10.1093/ecco-jcc/jjv096. Epub 2015 Jun 19. J Crohns Colitis. 2015. PMID: 26092578 Free PMC article. Review.
Three RCTs evaluated infusion reactions as a secondary outcome; another four RCTs included infusion reactions in the safety evaluation analysis; and 62 additional studies focused on various aspects of mechanism/s, risk, primary and secondary preventive measures, and manage …
Three RCTs evaluated infusion reactions as a secondary outcome; another four RCTs included infusion reactions in the safety evaluation analy …
Biosimilars in rheumatology.
Araújo FC, Gonçalves J, Fonseca JE. Araújo FC, et al. Pharmacol Res. 2019 Nov;149:104467. doi: 10.1016/j.phrs.2019.104467. Epub 2019 Sep 27. Pharmacol Res. 2019. PMID: 31568820 Review.
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adalimumab and rituximab biosimilars. ...
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adali …
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
Wong U, Cross RK. Wong U, et al. Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1039-1046. doi: 10.1080/17425255.2017.1377180. Epub 2017 Sep 11. Expert Opin Drug Metab Toxicol. 2017. PMID: 28876147 Review.
Primary and secondary non-response to infliximab are common in patients with inflammatory bowel disease and remain a management challenge in clinical practice. ...An algorithm for evaluation and management of non-response to infliximab is provided. Preventative meas …
Primary and secondary non-response to infliximab are common in patients with inflammatory bowel disease and remain a management chall …
The pharmacotherapeutic management of pediatric Crohn's disease.
Zimmerman L, Bousvaros A. Zimmerman L, et al. Expert Opin Pharmacother. 2019 Dec;20(17):2161-2168. doi: 10.1080/14656566.2019.1659778. Epub 2019 Oct 1. Expert Opin Pharmacother. 2019. PMID: 31574236 Review.
Introduction: Crohn's disease (CD) is a chronic inflammatory condition that can occur throughout the gastrointestinal tract. ...Immunomodulators (thiopurines, methotrexate) and biologics (infliximab, adalimumab) may be employed for maintenance of remission to preven …
Introduction: Crohn's disease (CD) is a chronic inflammatory condition that can occur throughout the gastrointestinal tract. ...Immun …
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.
Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Gelfand JM, et al. Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644. Epub 2017 Oct 13. Neurology. 2017. PMID: 29030454 Free PMC article.
OBJECTIVE: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis factor-α. ...RESULTS: Of 66 patients with CNS sarcoidosis (27 definite, 39 probable) treated with infliximab for a median of 1.5 yea …
OBJECTIVE: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis …
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.
Hemperly A, Vande Casteele N. Hemperly A, et al. Clin Pharmacokinet. 2018 Aug;57(8):929-942. doi: 10.1007/s40262-017-0627-0. Clin Pharmacokinet. 2018. PMID: 29330783 Review.
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). ...The administration of infliximab is weight-based and the drug
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to seve
Anti-TNF-alpha-induced lupus.
De Bandt M. De Bandt M. Arthritis Res Ther. 2019 Nov 12;21(1):235. doi: 10.1186/s13075-019-2028-2. Arthritis Res Ther. 2019. PMID: 31718696 Free PMC article. No abstract available.
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW Jr, Langholff W, Sandborn WJ. Lichtenstein GR, et al. Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501. doi: 10.1093/ibd/izx072. Inflamm Bowel Dis. 2018. PMID: 29462395 Free PMC article.
BACKGROUND: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn's disease (CD) therapy. ...Infliximab dose was not associated with mortality or serious infection. An increased risk of serious infection w …
BACKGROUND: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn's dise …
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.
Subedi S, Gong Y, Chen Y, Shi Y. Subedi S, et al. Drug Des Devel Ther. 2019 Jul 23;13:2491-2502. doi: 10.2147/DDDT.S200147. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31413544 Free PMC article. Review.
Anti-infliximab antibody is thought to be responsible for the LOR and infusion reactions. However, the mechanism underlying the formation of anti-infliximab antibody and its side effects remains unclear. ...This review discusses the efficacy of infliximab as …
Anti-infliximab antibody is thought to be responsible for the LOR and infusion reactions. However, the mechanism underlying the forma …
15,194 results
Jump to page
Feedback